Redeye updates its estimates and valuation following MedCap’s Q3 2026 report. Sales were in line with our estimate, while adjusted EBITA beat by c16% on a 20.9% margin. We nudge down our fair value to SEK600 (SEK620), mainly on a higher WACC.
LÄS MER
